

SARS-CoV-2 Variant of Concern 202012/01 has about twofold replicative advantage and is acquiring concerning mutations

Frederic Grabowski¹, Grzegorz Preibisch², Stanisław Giziński³, Marek Kochańczyk^{1,*} and Tomasz Lipniacki^{1,*}




Figure S1. The replicative advantage of VOC over 20A.EU1 in England, based on COG. Ratio of VOC to 20A.EU1 genomes collected from pillar 2 tests in weeks 38–51 in England. The trend line is fitted to data points from weeks 43–51 (green) and from weeks 43–47 (blue). The weekly growth rate is 1.92 [95% CI: 1.80–2.04] for weeks 43–51 and 2.20 [95% CI: 1.98–2.43] for weeks 43–47. The estimated R ratio is $Rt^{VOC} / Rt^{20A.EU1} = 1.87$ [95% CI: 1.76–1.98] for weeks 43–51 and 2.13 [95% CI: 1.93–2.35] for weeks 43–47.